Drugmakers seek details on use of ctDNA as a biomarker or early endpoint
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsDiagnostics/IVDsNorth AmericaPharmaceuticalsPreclinical studyRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsDiagnostics/IVDsNorth AmericaPharmaceuticalsPreclinical study